Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

Jonathan Corren; Mario Castro; Linda B. Ford; Jonathan A. Bernstein; Shyamalie Jayawardena; Jaman Maroni; Paul Rowe; Nikhil Amin; Gianluca Pirozzi; Neil M.H. Graham; Asif Khan; Laurent Eckert; Ariel Teper

doi:10.1016/j.anai.2019.04.028

Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

Jonathan Corren, Mario Castro, Linda B. Ford, Jonathan A. Bernstein, Shyamalie Jayawardena, Jaman Maroni, Paul Rowe, Nikhil Amin, Gianluca Pirozzi, Neil M.H. Graham, Asif Khan, Laurent Eckert, Ariel Teper

Research output: Contribution to journal › Article › peer-review

13 Scopus citations

Original language	English
Pages (from-to)	222-224.e1
Journal	Annals of Allergy, Asthma and Immunology
Volume	123
Issue number	2
DOIs	https://doi.org/10.1016/j.anai.2019.04.028
State	Published - Aug 2019

Access to Document

10.1016/j.anai.2019.04.028

Cite this

Corren, J., Castro, M., Ford, L. B., Bernstein, J. A., Jayawardena, S., Maroni, J., Rowe, P., Amin, N., Pirozzi, G., Graham, N. M. H., Khan, A., Eckert, L., & Teper, A. (2019). Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. Annals of Allergy, Asthma and Immunology, 123(2), 222-224.e1. https://doi.org/10.1016/j.anai.2019.04.028

@article{f1904d9abe7d49eb9dd795270899cfe0,

title = "Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history",

author = "Jonathan Corren and Mario Castro and Ford, {Linda B.} and Bernstein, {Jonathan A.} and Shyamalie Jayawardena and Jaman Maroni and Paul Rowe and Nikhil Amin and Gianluca Pirozzi and Graham, {Neil M.H.} and Asif Khan and Laurent Eckert and Ariel Teper",

note = "Funding Information: Funding Sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals . Medical writing/editorial assistance provided by Alessia Piazza, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals . ClinicalTrials.gov identifier: NCT01854047 . Funding Information: Disclosures: J. Corren: reports research funding from Sanofi. M. Castro received funding to Washington University for participation in a dupilumab clinical trial from Sanofi. L. B. Ford received grant support from 3M, Aimmune, AstraZeneca, DBV Technologies, Genentech, GlaxoSmithKline, Glenmark, Hoffmann La Roche, Novartis, Novum, Pearl, Sanofi, and Teva and served as a National Consultant for Sanofi. J. A. Bernstein conducted research for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, and Teva; served as a consultant for AstraZeneca and GlaxoSmithKline; served as a speaker for AstraZeneca; and served as the Editor-in-Chief of the Journal of Asthma. S. Jayawardena, P. Rowe, G. Pirozzi, A. Teper, A. Khan, and L. Eckert are employees of Sanofi, and may hold stock and/or stock options in the company. J. Maroni, N. Amin, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc.Funding Sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals. Medical writing/editorial assistance provided by Alessia Piazza, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals. ClinicalTrials.gov identifier: NCT01854047.",

year = "2019",

month = aug,

doi = "10.1016/j.anai.2019.04.028",

language = "English",

volume = "123",

pages = "222--224.e1",

journal = "Annals of Allergy, Asthma and Immunology",

issn = "1081-1206",

number = "2",

}

Corren, J, Castro, M, Ford, LB, Bernstein, JA, Jayawardena, S, Maroni, J, Rowe, P, Amin, N, Pirozzi, G, Graham, NMH, Khan, A, Eckert, L & Teper, A 2019, 'Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history', Annals of Allergy, Asthma and Immunology, vol. 123, no. 2, pp. 222-224.e1. https://doi.org/10.1016/j.anai.2019.04.028

TY - JOUR

T1 - Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

AU - Corren, Jonathan

AU - Castro, Mario

AU - Ford, Linda B.

AU - Bernstein, Jonathan A.

AU - Jayawardena, Shyamalie

AU - Maroni, Jaman

AU - Rowe, Paul

AU - Amin, Nikhil

AU - Pirozzi, Gianluca

AU - Graham, Neil M.H.

AU - Khan, Asif

AU - Eckert, Laurent

AU - Teper, Ariel

N1 - Funding Information: Funding Sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals . Medical writing/editorial assistance provided by Alessia Piazza, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals . ClinicalTrials.gov identifier: NCT01854047 . Funding Information: Disclosures: J. Corren: reports research funding from Sanofi. M. Castro received funding to Washington University for participation in a dupilumab clinical trial from Sanofi. L. B. Ford received grant support from 3M, Aimmune, AstraZeneca, DBV Technologies, Genentech, GlaxoSmithKline, Glenmark, Hoffmann La Roche, Novartis, Novum, Pearl, Sanofi, and Teva and served as a National Consultant for Sanofi. J. A. Bernstein conducted research for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Sanofi, and Teva; served as a consultant for AstraZeneca and GlaxoSmithKline; served as a speaker for AstraZeneca; and served as the Editor-in-Chief of the Journal of Asthma. S. Jayawardena, P. Rowe, G. Pirozzi, A. Teper, A. Khan, and L. Eckert are employees of Sanofi, and may hold stock and/or stock options in the company. J. Maroni, N. Amin, and N. M. H. Graham are employees and shareholders of Regeneron Pharmaceuticals, Inc.Funding Sources: Research sponsored by Sanofi and Regeneron Pharmaceuticals. Medical writing/editorial assistance provided by Alessia Piazza, PhD, of Excerpta Medica, funded by Sanofi Genzyme and Regeneron Pharmaceuticals. ClinicalTrials.gov identifier: NCT01854047.

PY - 2019/8

Y1 - 2019/8

UR - http://www.scopus.com/inward/record.url?scp=85066781388&partnerID=8YFLogxK

U2 - 10.1016/j.anai.2019.04.028

DO - 10.1016/j.anai.2019.04.028

M3 - Article

C2 - 31075309

AN - SCOPUS:85066781388

SN - 1081-1206

VL - 123

SP - 222-224.e1

JO - Annals of Allergy, Asthma and Immunology

JF - Annals of Allergy, Asthma and Immunology

IS - 2

ER -

Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history

Access to Document

Other files and links

Cite this